

Study: **ENGOT-cx12**

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

MaNGO Sites:

Prov	City	Site	Principal Investigator	Active
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo	